Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease

For almost two decades, the management of patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) was based on the optimal glycemic and blood pressure control as well as on the adequate blockade of the renin-angiotensin-system. Over the past few years, sodium-glucose co-transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgianos, Panagiotis I., Vaios, Vasilios, Roumeliotis, Stefanos, Leivaditis, Konstantinos, Eleftheriadis, Theodoros, Liakopoulos, Vassilios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874759/
https://www.ncbi.nlm.nih.gov/pubmed/35207711
http://dx.doi.org/10.3390/jpm12020223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874759/
https://www.ncbi.nlm.nih.gov/pubmed/35207711
http://dx.doi.org/10.3390/jpm12020223

Ejemplares similares